NASDAQ:PBYIPuma Biotechnology Stock Price, Forecast & News

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PBYI shares have increased by 16.6% and is now trading at $10.81. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Puma Biotechnology.

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Puma Biotechnology.

Puma Biotechnology Inc (NASDAQ:PBYI) issued its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.77) by $0.34. The biopharmaceutical company earned $51.20 million during the quarter, compared to analyst estimates of $44.42 million. Puma Biotechnology had a negative return on equity of 500.98% and a negative net margin of 36.72%. The business's quarterly revenue was down 48.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.21 EPS. View Puma Biotechnology's earnings history.

10 analysts have issued 12-month target prices for Puma Biotechnology's shares. Their forecasts range from $6.00 to $17.00. On average, they anticipate Puma Biotechnology's stock price to reach $12.63 in the next twelve months. This suggests a possible upside of 16.8% from the stock's current price. View analysts' price targets for Puma Biotechnology.

Headlines about PBYI stock have trended very negative recently, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Puma Biotechnology earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutPuma Biotechnology.

Puma Biotechnology saw a decline in short interest in May. As of May 15th, there was short interest totaling 7,870,000 shares, a decline of 6.8% from the April 30th total of 8,440,000 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is currently 5.8 days. Approximately 23.2% of the shares of the stock are short sold. View Puma Biotechnology's Current Options Chain.

Some companies that are related to Puma Biotechnology include Theravance Biopharma (TBPH), Ironwood Pharmaceuticals (IRWD), Zogenix (ZGNX), Heron Therapeutics (HRTX), Akebia Therapeutics (AKBA), Y-mAbs Therapeutics (YMAB), Opko Health (OPK), Arcus Biosciences (RCUS), CytoDyn (CYDY), BELLUS Health (BLUSF), Akcea Therapeutics (AKCA), Dicerna Pharmaceuticals (DRNA), Amneal Pharmaceuticals (AMRX), Innoviva (INVA) and Constellation Pharmaceuticals (CNST). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG).

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Puma Biotechnology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (8.99%), BlackRock Inc. (7.16%), Fred Alger Management LLC (5.93%), Camber Capital Management LP (4.95%), Federated Hermes Inc. (2.56%) and Acadian Asset Management LLC (2.22%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Charles R Eyler, Douglas M Hunt and Richard Paul Bryce. View institutional ownership trends for Puma Biotechnology.

PBYI stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Ikarian Capital LLC, WINTON GROUP Ltd, Deutsche Bank AG, Rafferty Asset Management LLC, Parametric Portfolio Associates LLC, Two Sigma Advisers LP, and Jane Street Group LLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt, and Richard Paul Bryce. View insider buying and selling activity for Puma Biotechnology.

PBYI stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Sofinnova Investments Inc., Fred Alger Management LLC, Tang Capital Management LLC, Federated Hermes Inc., UBS Group AG, Trexquant Investment LP, and Thrivent Financial for Lutherans. View insider buying and selling activity for Puma Biotechnology.

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBYI stock can currently be purchased for approximately $10.81.

Puma Biotechnology has a market capitalization of $425.52 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.

The official website for Puma Biotechnology is www.pumabiotechnology.com.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]